Revelation Biosciences, Inc. REVB
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.74M | 1.72M | 1.61M | 1.02M | 1.14M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.66M | 3.09M | 2.57M | 1.94M | 2.46M |
| Operating Income | -3.66M | -3.09M | -2.57M | -1.94M | -2.46M |
| Income Before Tax | -3.32M | -3.01M | -2.51M | -1.91M | -2.44M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.32M | -3.01M | -2.51M | -1.91M | -2.44M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.32M | -3.01M | -2.51M | -1.91M | -2.44M |
| EBIT | -3.66M | -3.09M | -2.57M | -1.94M | -2.46M |
| EBITDA | -3.65M | -3.09M | -2.57M | -1.94M | -2.45M |
| EPS Basic | -6.08 | -18.97 | -11.53 | -49.51 | -196.26 |
| Normalized Basic EPS | -3.80 | -4.10 | -7.21 | -12.62 | -53.29 |
| EPS Diluted | -6.08 | -18.97 | -11.53 | -49.51 | -196.26 |
| Normalized Diluted EPS | -3.80 | -4.10 | -7.21 | -12.62 | -53.29 |
| Average Basic Shares Outstanding | 547.10K | 458.20K | 217.70K | 94.50K | 28.70K |
| Average Diluted Shares Outstanding | 547.10K | 458.20K | 217.70K | 94.50K | 28.70K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |